16.16

5.14% 0.79

After Hours: 16.15 -0.01 -0.06%

Oculis Holding Ag (OCS)

Overview News Price History Discussions Forecast

Oculis Holding Ag stock is traded at $16.16, with a volume of 56,065. It is up +5.14% in the last 24 hours and up +2.28% over the past month. Oculis Holding AG is a global biopharmaceutical company purposefully driven to save sight and improve eye care. It includes OCS-01, a topical retinal candidate for diabetic macular edema (DME); OCS-02, a topical biologic candidate for dry eye disease (DED); and OCS-05, a disease modifying candidate for acute optic neuritis (AON) and other neuro-ophtha disorders such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis.

Previous Close:

$15.37

Open:

$15.51

24h Volume:

56,065

Relative Volume:

1.12

Market Cap:

$678.36M

Revenue:

Net Income/Loss:

$-75.28M

P/E Ratio:

-11.38

EPS:

-1.42

Net Cash Flow:

$-57.45M

1W Performance:

+8.38%

1M Performance:

+2.28%

6M Performance:

+36.37%

1Y Performance:

+63.81%

1-Day Range:

$15.51

$16.32

1-Week Range:

$14.50

$16.32

52-Week Range:

$9.60

$18.00

Oculis Holding Ag Stock (OCS) Company Profile

Name

Oculis Holding Ag

Sector

Healthcare (1200)

Industry

Biotechnology (682)

Phone

Address

Employee

Twitter

Next Earnings Date

Latest SEC Filings

OCS's Discussions on Twitter

Compare OCS with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
OCS Oculis Holding Ag	16.16	678.36M	0	-75.28M	-57.45M	-1.42
VRTX Vertex Pharmaceuticals Inc	464.56	119.70B	10.63B	-479.80M	-1.35B	13.33
REGN Regeneron Pharmaceuticals Inc	754.87	82.75B	13.85B	4.65B	3.32B	35.06
ARGX Argen X Se Adr	614.59	36.73B	1.86B	-40.29M	-1.28B	-4.16
ALNY Alnylam Pharmaceuticals Inc	253.74	32.53B	2.09B	-332.26M	16.06M	-4.14
BNTX Biontech Se Adr	120.72	28.50B	3.30B	-501.07M	1.03B	11.54

Oculis Holding Ag Stock (OCS) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Dec-05-23	Initiated	Chardan Capital Markets	Buy
Oct-05-23	Initiated	Stifel	Buy
Jun-14-23	Initiated	BofA Securities	Buy
Jun-12-23	Initiated	H.C. Wainwright	Buy
Jun-08-23	Initiated	Robert W. Baird	Outperform
May-10-23	Initiated	Pareto	Buy
Apr-28-23	Initiated	Wedbush	Outperform

View All

Oculis Holding Ag Stock (OCS) Latest News

Nov 27, 2024

Where are the Opportunities in (OCS) - Stock Traders Daily

Nov 27, 2024

Oculis Publishes Notification of Transaction by Person Discharging Managerial Responsibilities - Marketscreener.com

Nov 27, 2024

Oculis Awards Equity Incentive to Director Arshad Khanani for Consulting Services | OCS Stock News - StockTitan

Nov 27, 2024

Nov 19, 2024

Oculis (NASDAQ:OCS) Shares Up 3.8%Here's Why - MarketBeat

Nov 19, 2024

Nov 17, 2024

(OCS) Investment Analysis - Stock Traders Daily

Nov 17, 2024

Nov 13, 2024

Is Oculis Holding (OCS) Top Performing European Stock Heading into 2025? - Insider Monkey

Nov 13, 2024

Oculis to Present at the Stifel 2024 Healthcare Conference - The Manila Times

Nov 13, 2024

Oculis (OCS) to Present at Stifel Healthcare Conference: CFO Fireside Chat Announced | OCS Stock News - StockTitan

Nov 13, 2024

Nov 12, 2024

Oculis Holding AG Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com

Nov 07, 2024

Oculis Reports Q3 2024 Financial Results and Provides Company Updates - GlobeNewswire

Nov 07, 2024

Oculis birtir uppgjör fyrir þriðja ársfjórðung 2024 og kynnir nýjustu áfanga í rekstri félagsins - GlobeNewswire Inc.

Nov 07, 2024

Nov 05, 2024

Oculis (OCS) Scheduled to Post Quarterly Earnings on Thursday - MarketBeat

Nov 05, 2024

Nov 04, 2024

Oculis (NASDAQ:OCS) Hits New 12-Month HighWhat's Next? - MarketBeat

Nov 04, 2024

Oculis: Lack Of Coverage Only Real Risk For This Solid Company - Seeking Alpha

Nov 04, 2024

Nov 03, 2024

abrdn plc Sells 279,879 Shares of Oculis Holding AG (NASDAQ:OCS) - MarketBeat

Nov 03, 2024

Nov 01, 2024

Oculis (NASDAQ:OCS) Sees Strong Trading VolumeHere's Why - MarketBeat

Nov 01, 2024

Oct 30, 2024